Trial · NCT01430403
Results by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 50
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Occurrence of One or More Asthma Exacerbations (All Treatment Steps [Steps 2-5]) | Treatment Steps 2-5: Omalizumab | 11.3 | Percent of adjusted prevalence | ||
| Occurrence of One or More Asthma Exacerbations (All Treatment Steps [Steps 2-5]) | Treatment Steps 2-5: Placebo | 21.0 | Percent of adjusted prevalence | ||
| Occurrence of One or More Asthma Exacerbations (Treatment Steps 2-4) | Treatment Steps 2-4: Omalizumab | 8.4 | Percent of adjusted prevalence | ||
| Occurrence of One or More Asthma Exacerbations (Treatment Steps 2-4) | Treatment Steps 2-4:Inhaled Corticosteroid Boost Therapy (ICS) | 11.1 | Percent of adjusted prevalence | ||
| Virus-induced Exacerbations as Measured by an Exacerbation That is Associated With a Virus Detected Using the Nasal Mucus Samples | Samples With Exacerbations | 71.8 | Percent Samples with virus | ||
| Virus-induced Exacerbations as Measured by an Exacerbation That is Associated With a Virus Detected Using the Nasal Mucus Samples | Samples Without Exacerbations | 40.4 | Percent Samples with virus | ||
| Severity of Asthma Symptoms Associated With a Viral Infection:Omalizumab vs. Placebo | Omalizumab | 1.2 | Standard Error 0.09 | Maximum Symptoms Days | |
| Severity of Asthma Symptoms Associated With a Viral Infection:Omalizumab vs. Placebo | Placebo | 1.8 | Standard Error 0.23 | Maximum Symptoms Days | |
| Number of Exacerbations Evaluated Monthly With Viral Respiratory Infections: Omalizumab vs. Placebo | Omalizumab | 5.6 | Standard Error 0.19 | Total Number of Viral Infections | |
| Number of Exacerbations Evaluated Monthly With Viral Respiratory Infections: Omalizumab vs. Placebo | Placebo | 5.8 | Standard Error 0.13 | Total Number of Viral Infections | |
| Composite Asthma Severity Index (CASI), Treatment Steps 2-5: Omalizumab vs. Placebo | Treatment Steps 2-5: Omalizumab | 4.9 | Standard Error 0.15 | CASI Score | |
| Composite Asthma Severity Index (CASI), Treatment Steps 2-5: Omalizumab vs. Placebo | Treatment Steps 2-5: Placebo | 5.5 | Standard Error 0.27 | CASI Score | |
| Composite Asthma Severity Index (CASI), Treatment Steps 2-4: Omalizumab vs. ICS | Treatment Steps 2-4: Omalizumab | 4.6 | Standard Error 0.23 | CASI Score | |
| Composite Asthma Severity Index (CASI), Treatment Steps 2-4: Omalizumab vs. ICS | Treatment Steps 2-4:Inhaled Corticosteroid Boost Therapy (ICS) | 4.8 | Standard Error 0.24 | CASI Score | |
| Spirometry Measurements: Forced Expiratory Volume in 1 Second (FEV1) % Predicted, Treatment Steps 2-5:Omalizumab vs. Placebo | Treatment Steps 2-5: Omalizumab | 92.2 | Standard Error 0.79 | percent predicted FEV1 | |
| Spirometry Measurements: Forced Expiratory Volume in 1 Second (FEV1) % Predicted, Treatment Steps 2-5:Omalizumab vs. Placebo | Treatment Steps 2-5: Placebo | 92.5 | Standard Error 1.38 | percent predicted FEV1 | |
| Spirometry Measurements: Forced Expiratory Volume in 1 Second (FEV1) % Predicted , Treatment Steps 2-4: Omalizumab vs. ICS | Treatment Steps 2-4: Omalizumab | 93.2 | Standard Error 1.15 | percent predicted FEV1 | |
| Spirometry Measurements: Forced Expiratory Volume in 1 Second (FEV1) % Predicted , Treatment Steps 2-4: Omalizumab vs. ICS | Treatment Steps 2-4:Inhaled Corticosteroid Boost Therapy (ICS) | 90.8 | Standard Error 1.16 | percent predicted FEV1 | |
| Spirometry Measurements: FEV1:FVCx100, Treatment Steps 2-5: Omalizumab vs. Placebo | Treatment Steps 2-5: Omalizumab | 78.6 | Standard Error 0.44 | percent FEV1/FVC ratio | |
| Spirometry Measurements: FEV1:FVCx100, Treatment Steps 2-5: Omalizumab vs. Placebo | Treatment Steps 2-5: Placebo | 78.4 | Standard Error 0.78 | percent FEV1/FVC ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01430403/results